7WOLTERS L M, NIESTERS H G, de MAN R A, et al.Nucleoside analogues for chronic hepatitis B [J]. Eur J Gast roenterol Hepatol,2001,13( 12):1499-1506.
8BENHAMOUY,BOCHET M,THIBAULT V, et al. Safety and efficacy of adefovirdipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus:an open-label pilot study [J]. Lancet,2001,358(9283):718-723.
3Benhamou, Y. Bochet, M. Tribault, V. et at:safety and efficacy of long term DPADV for 3TC resistant HBV in HIV infected patients. J Hepatol, 2002; 36(suppl. 1)Abst 496.
5Delangerre, C. Marcelin, A. G. Thibauit, V. et al: HIV-1 reverse transcriptase resistance mutations profile in HBV/HIV-1 coinfected patients treated by a combination of DPADV10mg once daily and 3TC for their HBV infection, Antivir Ther, 2001 ; 6 (suppl. 1)Abst 112.
6Delaugerre, C. Marcelin, A. G. Thibault, V. et al: HIV-1 reverse transcriptase resistance mutations in HBV/HIV coinfected patients treated for HBV chronic infection once daily with 10mg of DPADV combined with 3TC. AAC,2002,46(5) :1586-1593.
7Benhamou, Y. Bochet, M. Tribault, V. et al:safety and efficacy of DNADVin patients coinfected with HIV-1 and 3TC resistant HBV:An open label pilot study. Lancet, 2001; 358(9283):718-728.
8Noble, S and Goa, K. L. Adefovir Dipivoxil.Drugs, 1999; 58 (3) :479-487.
9Tanji N. Tanji, K. Kambhan. N. et al: Adefovir Nephrotoxieity: Possible role of mitochondrial DNA depletion. Hum pathol, 2001 ; 32 (7) : 734-742.
10Peters, M. Hann, H. W. Martin, P. et al:DPADV alone and in combination with 3TC suppresses 3TC HBV replication: 16 week interim analysis. J Hepatol, 2002; 36 (suool. 1)Abst 13.
